Yao Chang Xu
Chief Executive Officer chez ABBISKO CAYMAN LIMITED
Fortune : 31 M $ au 31/03/2024
Profil
Yao Chang Xu is the founder of Abbisko Therapeutics Co., Ltd.
(founded in 2016) and Abbisko Cayman Ltd.
(founded in 2016).
He is currently a Director at Abbisko Hong Kong Ltd.
(since 2018), Wuxi Abbisko Biomedical Technology Co. Ltd.
(since 2020), and Abbisko Therapeutics Australia Pty Ltd.
(since 2020).
Dr. Xu's former positions include Executive Director at Novartis International AG (2006-2012), Head-Discovery Chemistry at Eli Lilly & Co. (1993-2006), and General Manager at Hansoh Pharmaceutical Group Co., Ltd.
(2012-2016) and Shanghai Hansoh Biomedical Co. Ltd.
(2012-2016).
Dr. Xu received his doctorate degree from The University of Chicago in 1988 and his undergraduate degree from Nanjing University in 1982.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ABBISKO CAYMAN LIMITED
11,86% | 02/04/2024 | 83 297 074 ( 11,86% ) | 31 M $ | 31/03/2024 |
Postes actifs de Yao Chang Xu
| Sociétés | Poste | Début |
|---|---|---|
| ABBISKO CAYMAN LIMITED | Chief Executive Officer | 28/03/2018 |
Abbisko Therapeutics Co., Ltd.
 Abbisko Therapeutics Co., Ltd. Pharmaceuticals: MajorHealth Technology Abbisko Therapeutics Co., Ltd. engages in the research and development of biomedicine and biotechnology. Its business includes technology transfer, technical advisory, and technical services. The company was founded on April 12, 2016 and is headquartered in Shanghai, China. | Chief Executive Officer | 12/04/2016 |
| Abbisko Hong Kong Ltd. | Director/Board Member | 01/04/2018 |
| Wuxi Abbisko Biomedical Technology Co. Ltd. | Director/Board Member | 01/07/2020 |
| Abbisko Therapeutics Australia Pty Ltd. | Director/Board Member | 01/12/2020 |
Anciens postes connus de Yao Chang Xu
| Sociétés | Poste | Fin |
|---|---|---|
| HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED | Corporate Officer/Principal | 01/03/2016 |
| Shanghai Hansoh Biomedical Co. Ltd. | Corporate Officer/Principal | 01/03/2016 |
Novartis International AG
 Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Director/Board Member | 01/03/2012 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01/01/2006 |
Formation de Yao Chang Xu
| The University of Chicago | Doctorate Degree |
| Nanjing University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED | Health Technology |
| ABBISKO CAYMAN LIMITED | Health Technology |
| Entreprise privées | 6 |
|---|---|
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
Abbisko Therapeutics Co., Ltd.
Abbisko Therapeutics Co., Ltd. Pharmaceuticals: MajorHealth Technology Abbisko Therapeutics Co., Ltd. engages in the research and development of biomedicine and biotechnology. Its business includes technology transfer, technical advisory, and technical services. The company was founded on April 12, 2016 and is headquartered in Shanghai, China. | Health Technology |
| Shanghai Hansoh Biomedical Co. Ltd. | |
| Abbisko Hong Kong Ltd. | |
| Wuxi Abbisko Biomedical Technology Co. Ltd. | |
| Abbisko Therapeutics Australia Pty Ltd. |
